Exploring combination treatment with a HER2 and a Pirin inhibitor in HER2-overexpressing breast cancer cells
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
Heidelberg, Universität Heidelberg, Dissertation, 2021
- Keyword
-
Krebs
Brustkrebs
- Event
-
Veröffentlichung
- (where)
-
Heidelberg
- (who)
-
Universitätsbibliothek Heidelberg
- (when)
-
2022
- Creator
- Contributor
-
Jechlinger, Martin
- DOI
-
10.11588/heidok.00032427
- URN
-
urn:nbn:de:bsz:16-heidok-324279
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:44 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Boucher, Matthew
- Jechlinger, Martin
- Universitätsbibliothek Heidelberg
Time of origin
- 2022
Other Objects (12)
Photoimmunotherapy of HER2-expressing Breast Cancer Cells
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
HER2 dynamics and EGF-NRG1 shape the response of HER2-targeted therapies in breast cancer
EGFR Expression in HER2-Driven Breast Cancer Cells
Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
Prognostic effect of HER2 evolution from primary breast cancer to breast cancer metastases
Häufigkeit der EGFR- und HER2-Ausprägung sowie HER2-Genamplifikation beim Gallengangskarzinom
Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells
Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial
HER2 Dimerization Inhibitor Pertuzumab – Mode of Action and Clinical Data in Breast Cancer
Targeting breast cancer stem cells with HER2-specific antibodies and natural killer cells
Photoimmunotherapy of HER2-expressing Breast Cancer Cells
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
HER2 dynamics and EGF-NRG1 shape the response of HER2-targeted therapies in breast cancer
EGFR Expression in HER2-Driven Breast Cancer Cells
Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
Prognostic effect of HER2 evolution from primary breast cancer to breast cancer metastases
Häufigkeit der EGFR- und HER2-Ausprägung sowie HER2-Genamplifikation beim Gallengangskarzinom
Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells
Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial
HER2 Dimerization Inhibitor Pertuzumab – Mode of Action and Clinical Data in Breast Cancer
Targeting breast cancer stem cells with HER2-specific antibodies and natural killer cells
Photoimmunotherapy of HER2-expressing Breast Cancer Cells
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
HER2 dynamics and EGF-NRG1 shape the response of HER2-targeted therapies in breast cancer
EGFR Expression in HER2-Driven Breast Cancer Cells
Quantification of EGFR-HER2 Heterodimers in HER2-Overexpressing Breast Cancer Cells Using Liquid-Phase Electron Microscopy
Prognostic effect of HER2 evolution from primary breast cancer to breast cancer metastases
Häufigkeit der EGFR- und HER2-Ausprägung sowie HER2-Genamplifikation beim Gallengangskarzinom
Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells
Clinical Characteristics and Prognosis of HER2-0 and HER2-Low-Positive Breast Cancer Patients: Real-World Data from Patients Treated with Neoadjuvant Chemotherapy
The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial
HER2 Dimerization Inhibitor Pertuzumab – Mode of Action and Clinical Data in Breast Cancer